Dr. Tracey Lynn O'Connor, MD

Dr. O'Connor practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. O'Connor's NPI, 1043201411, was assigned on November 3, 2005. Dr. O'Connor graduated from Jacobs School of Medicine and Biomedical Sciences in 1997. Dr. O'Connor holds Florida license ME163139.

Dr. O'Connor's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. O'Connor also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. O'Connor's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. O'Connor to 1 more breast imaging center, 1 group practice or clinic, 1 hospital outpatient department and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. O'Connor practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. O'Connor's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. O'Connor is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. O'Connor's licenses on file in 2 states: Florida and New York.

Dmand AI lists breast cancer among the conditions Dr. O'Connor treats.

CMS data shows 198 Medicare services from Dr. O'Connor across 4 procedure codes in 2024, for 101 Medicare patients. Medicare paid $18,328 for them.

CMS counts 101 Medicare patients who saw Dr. O'Connor in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have cancer, and 73% have high cholesterol. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. O'Connor's median patient age at 65, with 98% women.

In 2024, Dr. O'Connor wrote 273 Medicare Part D claims for 90 patients. 82% of them were for generic drugs. CMS names the drug for 179 of them, across 6 drugs with 11 or more claims each, at $258,405 in total drug cost. In 2023, CMS named 53 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. O'Connor for performance year 2024, reported as part of a group. Dr. O'Connor accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. O'Connor as offering telehealth.

Dmand AI links 33 papers to Dr. O'Connor, published from 2007 to 2021. 2011 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Survivors and Antineoplastic Combined Chemotherapy Protocols. Dr. O'Connor has published most often in J Natl Compr Canc Netw. Dr. O'Connor's most frequent co-authors are Crystal S. Denlinger, MD, Debra L. Friedman, MD and Mindy E. Goldman, MD.

Dmand AI links Dr. O'Connor to 9 clinical trials. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Arthralgia. Roswell Park Cancer Institute sponsors the most, 7.

CMS Open Payments shows 13 general payments to Dr. O'Connor from 7 drug and device companies from 2017 to 2025. Travel and lodging make up the largest share, 90% of the total. Amgen Inc. paid the most, $6,839.

Dr. O'Connor graduated from Jacobs School of Medicine and Biomedical Sciences in 1997.

Dr. O'Connor is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.